US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Mobia Medical priced at the midpoint but traded poorly after opening below issue price, triggering classic broken IPO dynamics throughout the first session.</li>
<li>Mobia Medical priced at the midpoint but traded poorly after opening below issue price, triggering classic broken IPO dynamics throughout the first session.</li>
<li>Recovery will likely depend on strong execution and a convincing first earnings report to rebuild institutional confidence and stabilize sentiment.</li>
</ul>


Mobia Medical priced at the midpoint but traded poorly after opening below issue price, triggering classic broken IPO dynamics throughout the first session.
Mobia Medical priced at the midpoint but traded poorly after opening below issue price, triggering classic broken IPO dynamics throughout the first session.
Recovery will likely depend on strong execution and a convincing first earnings report to rebuild institutional confidence and stabilize sentiment.


Mobia Medical (MOBI): Oversubscribed but Unsupported, IPO Falters in Aftermarket Trading

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.82/10 🏦 Deal Quality &amp; Underwriters: 9/10 Mobia Medical is coming to market offering approximately 10 million shares at $14 to $16, targeting roughly $150 million in proceeds.</li><li>The company operates in the medical technology space, focused on devices and solutions tied to procedural efficiency and patient outcomes.</li><li>The setup of this current mid-cap healthcare IPO reflects a high-quality underwriting group, relatively tight float, and a demand profile that is showing constructive early signs during the bookbuilding process.</li></ul>

✅ IPO PROPHET RATING: 7.82/10 🏦 Deal Quality &amp; Underwriters: 9/10 Mobia Medical is coming to market offering approximately 10 million shares at $14 to $16, targeting roughly $150 million in proceeds.The company operates in the medical technology space, focused on devices and solutions tied to procedural efficiency and patient outcomes.The setup of this current mid-cap healthcare IPO reflects a high-quality underwriting group, relatively tight float, and a demand profile that is showing constructive early signs during the bookbuilding process.

<ul>
<li>Mobia Medical’s Vivistim System targets chronic stroke recovery with FDA-approved neuromodulation, addressing a large underserved market with potential to become standard of care.</li>
<li>Revenue more than doubled in 2025 to $32M with 81% gross margins, highlighting strong adoption, though losses widened due to continued commercialization investment.</li>
<li>Key risks include ongoing losses, reimbursement expansion, and adoption scalability, though medtech IPOs typically benefit from clearer revenue visibility versus biotech peers.</li>
</ul>


Mobia Medical’s Vivistim System targets chronic stroke recovery with FDA-approved neuromodulation, addressing a large underserved market with potential to become standard of care.
Revenue more than doubled in 2025 to $32M with 81% gross margins, highlighting strong adoption, though losses widened due to continued commercialization investment.
Key risks include ongoing losses, reimbursement expansion, and adoption scalability, though medtech IPOs typically benefit from clearer revenue visibility versus biotech peers.


Mobia Medical (MOBI): High-Growth Medtech Targeting a New Standard in Stroke Rehab

<ul><li>Mobia Medical, Inc. (Nasdaq: MOBI) has set terms for its initial public offering, marketing 10.0 million shares at a price range of $14 to $16 , implying a deal size of approximately $150 million at the midpoint.</li><li>At the midpoint price of $15 , the company would have an estimated post-offer market capitalization of approximately $500 million , based on 33.1 million shares outstanding following the offering.</li><li>BofA Securities, J.P. Morgan, and Goldman Sachs are leading the deal alongside BTIG and Wolfe | Nomura Alliance.</li></ul>

Mobia Medical, Inc. (Nasdaq: MOBI) has set terms for its initial public offering, marketing 10.0 million shares at a price range of $14 to $16 , implying a deal size of approximately $150 million at the midpoint.At the midpoint price of $15 , the company would have an estimated post-offer market capitalization of approximately $500 million , based on 33.1 million shares outstanding following the offering.BofA Securities, J.P. Morgan, and Goldman Sachs are leading the deal alongside BTIG and Wolfe | Nomura Alliance.

Mobia Medical Sets Terms on $150M IPO as Vivistim Platform Reframes Chronic Stroke Recovery

<ul>
<li>Mobia Medical is a commercial-stage medtech company targeting a $529M IPO valuation, offering the FDA-approved Vivistim system for chronic stroke recovery.</li>
<li>Proceeds will fund commercial expansion, R&amp;D, and clinical programs, supporting continued adoption of its neurostimulation-based stroke recovery platform.</li>
<li>The company has scaled rapidly, with 105% revenue growth in 2025 and over 1,000 total implants, including ~700 in the latest year.</li>
</ul>


Mobia Medical is a commercial-stage medtech company targeting a $529M IPO valuation, offering the FDA-approved Vivistim system for chronic stroke recovery.
Proceeds will fund commercial expansion, R&amp;D, and clinical programs, supporting continued adoption of its neurostimulation-based stroke recovery platform.
The company has scaled rapidly, with 105% revenue growth in 2025 and over 1,000 total implants, including ~700 in the latest year.


Mobia Medical (MOBI): Medical Device for Stroke Recovery Sets Terms for IPO

United States

Mobia Medical, Inc. is a medical device company. The Company develops, markets, and sells devices for the treatment of chronic ischemic stroke survivors living with life-altering motor impairments. Mobia Medical operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mobia Medical (MOBI US)

Mobia Medical (MOBI): Oversubscribed but Unsupported, IPO Falters in Aftermarket Trading

Mobia Medical's IPO priced at midpoint ($15.00), traded poorly, now needs strong execution and earnings report for recovery.

IPO Boutique

IPO Rating: Mobia Medical Inc.

✅ IPO PROPHET RATING: 7.82/10 🏦 Deal Quality & Underwriters: 9/10 Mobia Medical is coming to market offering approximately 10 million shares...

IPO Prophet

Mobia Medical (MOBI): High-Growth Medtech Targeting a New Standard in Stroke Rehab

Mobia Medical's Vivistim System shows promise in chronic stroke recovery with strong revenue growth, but faces risks in ongoing losses and...

IPO Boutique

Mobia Medical Sets Terms on $150M IPO as Vivistim Platform Reframes Chronic Stroke Recovery

Mobia Medical, Inc. (Nasdaq: MOBI) has set terms for its initial public offering, marketing 10.0 million shares at a price range of $14 to $16 ,...

IPO Prophet

Mobia Medical (MOBI): Medical Device for Stroke Recovery Sets Terms for IPO

Mobia Medical aims for $529M IPO to support growth of FDA-approved Vivistim system for stroke recovery, with rapid revenue growth and over 1,000...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Mobia Medical (MOBI): Oversubscribed but Unsupported, IPO Falters in Aftermarket Trading

​Mobia Medical's IPO priced at midpoint ($15.00), traded poorly, now needs strong execution and earnings report for recovery.

IPO Boutique

IPO Rating: Mobia Medical Inc.

✅ IPO PROPHET RATING: 7.82/10 🏦 Deal Quality & Underwriters: 9/10 Mobia Medical is coming to market offering approximately 10 million shares...

IPO Prophet

Mobia Medical (MOBI): High-Growth Medtech Targeting a New Standard in Stroke Rehab

​Mobia Medical's Vivistim System shows promise in chronic stroke recovery with strong revenue growth, but faces risks in ongoing losses and...

IPO Boutique

Mobia Medical Sets Terms on $150M IPO as Vivistim Platform Reframes Chronic Stroke Recovery

Mobia Medical, Inc. (Nasdaq: MOBI) has set terms for its initial public offering, marketing 10.0 million shares at a price range of $14 to $16 ,...

IPO Prophet

Mobia Medical (MOBI): Medical Device for Stroke Recovery Sets Terms for IPO

​Mobia Medical aims for $529M IPO to support growth of FDA-approved Vivistim system for stroke recovery, with rapid revenue growth and over 1,000...

IPO Boutique

Mobia Medical's IPO priced at midpoint ($15.00), traded poorly, now needs strong execution and earnings report for recovery.

Mobia Medical's Vivistim System shows promise in chronic stroke recovery with strong revenue growth, but faces risks in ongoing losses and...

Mobia Medical aims for $529M IPO to support growth of FDA-approved Vivistim system for stroke recovery, with rapid revenue growth and over 1,000...